Intraocular pressure lowering, change of antiapoptotic molecule expression, and neuroretinal changes by dorzolamide 2%/timolol 0.5% combination in a chronic ocular hypertension rat model

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 6, 2008, Pages 563-571

  Park, Hae Y ^a   Lee, Na Y ^a   Kim, Jie H ^a   Park, Chan K ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS INHIBITOR; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL XL; TIMOLOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; GLAUCOMA; INTRAOCULAR HYPERTENSION; MALE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RETINA GANGLION CELL; RETINA INJURY;

ANIMALS; BCL-X PROTEIN; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; GLIAL FIBRILLARY ACIDIC PROTEIN; INTRAOCULAR PRESSURE; MALE; OCULAR HYPERTENSION; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; RETINAL GANGLION CELLS; RNA, MESSENGER; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 57349110621     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2008.0039     Document Type: Article

References (56)

1. Kerrigan, L.A., Zack, D.J., Quigley, H.A., et al. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch. Ophthalmol. 115:1031-1035, 1997.
2. Quigley, H.A., Nickells, R.W., Kerrigan, L.A., et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest. Ophthalmol. Vis. Sci. 36:774-786, 1995.
3. Lam, T.T., Abler, A.S., Kwong, J.M., et al. N-methyl-D-aspartate (NMDA)-induced apoptosis in rat retina. Invest. Ophthalmol. Vis. Sci. 40:2391-2397, 1999.
4. Quigley, H.A., McKinnon, S.J., Zack, D.J., et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest. Ophthalmol. Vis. Sci. 41:3460-3466, 2000.
5. Stone, E.M., Fingert, J.H., Alward, W.L., et al. Identification of a gene that causes primary open angle glaucoma. Science 275:668-670, 1997.
6. Brubaker, R.F. Delayed functional loss in glaucoma. Am. J. Ophthalmol. 12:473-483, 1996.
7. Coleman, A.L. Glaucoma. Lancet 354:1803-1810, 1999.
8. Robert, N.W., and Leonard, A.L. Is neuroprotection a viable therapy for glaucoma? Arch. Ophthalmol. 117:1540-1544, 1999.
9. Walters, T.R., et al. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: A 1-month, randomized, comparative clinical trial. Surv. Ophthalmol. 49:26-35, 2004.
10. Konstas, A.G., et al. Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. Eye 18:893-899, 2004.
11. Higashiyama, M., et al. Improvement of the ocular bioavailability of timolol by sorbic acid. Int. J. Pharm. 272:91-98, 2004.
12. Tan, A.Y., et al. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing. J. Glaucoma 11:134-142, 2002.
13. Casini, A., et al. Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide. Bioorg. Med. Chem. Lett. 13:2867-2873, 2003.
14. Baudouin, C., and Lunardo, C. Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br. J. Ophthalmol. 82:39-42, 1998.
15. Lewis, R.A., Katz, G.J., Weiss, M.J., et al. Travoprost 0.004% with and without benzalkonium chloride: A comparison of safety and efficacy. J. Glaucoma 16:98-103, 2007.
16. Okabe, K., Kimura, H., Okabe, J., et al. Effect of benzalkonium chloride on transscleral drug delivery. Invest. Ophthalmol. Vis. Sci. 46:703-708, 2005.
17. Silver, L.H., et al. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am. J. Ophthalmol. 126:400-408, 1998.
18. Wistrand, P.J., Schenholm, M., and Lonnerholm, G. Carbonic anhydrase isoenzymes CA I and CA II in the human eye. Invest. Ophthalmol. Vis. Sci. 27:419-428, 1986.
19. Minckler, D.S., Bunt, A.H., and Johanson, G.W. Orthograde and retrograde axoplasmic transport during acute ocular hypertension in the monkey. Invest. Ophthalmol. Vis. Sci. 16:426-441, 1997.
20. Baptiste, D.C., Hartwick, A.T., Jollimore, C.A., et al. Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina. Invest. Ophthalmol. Vis. Sci. 43:2666-2676, 2002.
21. Yoles, E., Wheeler, L., and Schwartz, M. Alpha-2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest. Ophthalmol. Vis. Sci. 40:65-73, 1999.
22. Aktaş, Z., Gürelik, G., Akyürek, N., et al. Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model. Clin. Exp. Ophthalmol. 35:527-534, 2007.
23. Kim, H.S., Chang, Y.I., Kim, J.H., et al. Alteration of retinal intrinsic survival signal and effect of alpha2-adrenergic receptor agonist in the retina of the chronic ocular hypertension rat. Vis. Neurosci. 24:127-139, 2007.
24. Vidal-Sanz, M., Lafuente, M.P., Mayor, S., et al. Retinal ganglion cell death induced by retinal ischemia: Neuroprotective effects of two alpha-2 agonists. Surv. Ophthalmol. 45:261-267, 2001.
25. Wen, R., Cheng, T., Li, Y., et al. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J. Neurosci. 16:5986-9592, 1996.
26. Zhang, J., Wu, S.M., and Gross, R.L. Effects of beta-adrenergic blockers on glutamate-induced calcium signals in adult mouse retinal ganglion cells. Brain Res. 959:111-119, 2003.
27. Hirooka, K., Kelly, M.E., Baldridge, W.H., et al. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp. Eye Res. 70:611-621, 2000.
28. Wood, J.P., DeSantis, L., Chao, H.M., et al. Topically applied betaxolol attenuates ischaemia-induced effects to the rat retina and stimulates BDNF mRNA. Exp. Eye Res. 72:79-86, 2001.
29. Yue, T.L., Cheng, H.Y., Lysko, P.G., et al. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther. 263:92-98, 1992.
30. Weglicki, W.B., Mak, I.T., and Simic, M.G. Mechanisms of cardiovascular drugs as antioxidants. J. Mol. Cell. Cardiol. 22:1199-1208, 1990.
31. Hoyng, P.F.J., and van Beek, L.M. Pharmacological therapy for glaucoma: A review. Drugs 59:411-434, 2000.
32. Ormrod, D. and McClellan, K. Topical dorzolamide 2%/timolol 0.5%: A review of its use in the treatment of open-angle glaucoma. Drugs Aging 17:477-496, 2000.
33. Harris, A., Jonescu-Cuypers, C.P., Kagemann, L., et al. Effect of dorzolamide timolol combination versus timolol 0.5% on ocular blood flow in patients with primary open-angle glaucoma. Am. J. Ophthalmol. 132:490-495, 2001.
34. Januleviciene, I., Harris, A., Kagemann, L., et al. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Acta. Ophthalmol. Scand. 82:730-737, 2004.
35. Manni, G., Centofanti, M., Gregori, D., et al. The pulsatile ocular blood flow behavior in open-angle glaucoma patient after replacing timolol therapy with timolol and dorzolamide fixed combination: Preliminary study. Acta. Ophthalmol. Acand. Suppl. 236:55-56, 2002.
36. Martinez, A., and Sanchez, M. A comparison of the effects of 0.005% latanoprost and fixed combination dorzolamide/ timolol on retrobulbar haemodynamics in previously untreated glaucoma patients. Curr. Med. Res. Opin. 22:67-73, 2006.
37. Ared, O., Harris, A., Wolter, P., et al. Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol, and latanoprost in newly diagnosed open-angle glaucoma patients. Acta. Ophthalmol. Scand. 81:474-479, 2003.
38. Fuchsjager-Mayrl, G., Wally, B., Rainer, G., et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open-angle glaucoma and ocular hypertension. Br. J. Ophthalmol. 89:1293-1297, 2005.
39. Galassi, F., Sodi, A., Renieri, G., et al. Effects of timolol and dorzolamide on retrobulbar hemodynamics in patients with newly diagnosed primary open-angle glaucoma. Ophthalmologica 216:123-128, 2002.
40. Avunduk, A.M., Sari, A., Akyol, N., et al. The one-month effects of topical betaxolol, dorzolamide, and apraclonidine on ocular blood flow felocities in patients with newly diagnosed primary open-angle glaucoma. Ophthalmologica 215:361-365, 2001.
41. Wood, J.P.M., Melena, S.J., Chidlow, G., et al. The β-adrenoceptor anatagonist metipranolol and timolol are retinal neuroprotectants: Comparison with betaxolol. Exp. Eye Res. 76:505-516, 2003.
42. Yu, Z.K., Chen, Y.N., Aihara, M., et al. Effects of β-adrenergic receptor antagonist on oxidative stress in purified rat retinal ganglion cells. Mol. Vis. 13:833-839, 2007.
43. Kim, H.S., and Park, C.K. Retinal ganglion cell death is delayed by activation of retinal intrinsic cell survival program. Brain Res. 1057:17-28, 2005.
44. Levkovitch-Verbin, H., et al. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats. Invest. Ophthalmol. Vis. Sci. 43:402-410, 2002.
45. Ishii, Y., Kwong, J.M., and Caprioli, J. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 44:1982-1992, 2003.
46. Cory, S., and Adams, J.M. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat. Rev. Cancer 2:647-656, 2002.
47. Oltvai, Z.N., Milliman, C.L., and Korsmeyer, S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619, 1993.
48. Adams, J.M., and Cory, S. The Bcl-2 protein family: Arbiters of cell survival. Science 281:1322-1326, 1998.
49. Evan, G., and Littlewood, T. A matter of life and cell death. Science 281:1317-1322, 1998.
50. Zamzami, N., et al. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 16:2265-2282, 1998.
51. Schnitzer, J. Immunocytochemical studies on the development of astrocytes, Müller (glial) cells, and oligodendrocytes in the rabbit retina. Brain Res. Dev. Brain Res. 44:59-72, 1998.
52. Bjorklund, H., Bignami, A., and Dahl, D. Immunohistochemical demonstration of glial fibrillary acidic protein in normal rat Müller glia and retinal astrocytes. Neurosci. Lett. 54:363-368, 1985.
53. Guerin, C.J., Anderson, D.H., and Fisher, S.K. Changes in intermediate filament immunolabeling occur in response to retinal detachment and reattachment in primates. Invest. Ophthalmol. Vis. Sci. 31:1474-1482, 1990.
54. Lewis, G.P., and Fisher, S.K. Upregulation of glial fibrillary acidic protein in response to retinal injury: Its potential role in glial remodeling and a comparison to vimentin expression. Int. Rev. Cytol. 230:263-290, 2003.
55. Okada, M., Matsumura, M., Ogino, N., et al. Müller cells in detached human retina express glial fibrillary acidic protein and vimentin. Graefe's Arch. Clin. Exp. Ophthalmol. 228:467-474, 1990.
56. Stadelmann, C., and Lassmann, H. Detection of apoptosis in tissue sections. Cell Tissue Res. 301:19-31, 2000.